D-tryptophan-6-luteinzing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

L. Schwarstein, N. J. Aparicio, Andrew V Schally

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

Original languageEnglish
Pages (from-to)171-178
Number of pages8
JournalInternational Journal of Andrology
Volume5
Issue number2
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Tryptophan
Triptorelin Pamoate
Hormones
Gonadotropin-Releasing Hormone
Oligospermia
Spermatids
Therapeutics
Prolactin
Infertility
Testosterone
Spermatozoa
Biopsy
Serum

ASJC Scopus subject areas

  • Endocrinology

Cite this

D-tryptophan-6-luteinzing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia. / Schwarstein, L.; Aparicio, N. J.; Schally, Andrew V.

In: International Journal of Andrology, Vol. 5, No. 2, 01.01.1982, p. 171-178.

Research output: Contribution to journalArticle

@article{ae2a894941ff425dba536e7d75a6b368,
title = "D-tryptophan-6-luteinzing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia",
abstract = "D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.",
author = "L. Schwarstein and Aparicio, {N. J.} and Schally, {Andrew V}",
year = "1982",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "171--178",
journal = "International Journal of Andrology",
issn = "0105-6263",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - D-tryptophan-6-luteinzing hormone-releasing hormone in the treatment of normogonadotropic oligoasthenozoospermia

AU - Schwarstein, L.

AU - Aparicio, N. J.

AU - Schally, Andrew V

PY - 1982/1/1

Y1 - 1982/1/1

N2 - D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

AB - D-Tryptophan-6-LH-RH was assessed in the treatment of patients with normogonadotropic oligoasthenozoospermia in 18 subjects selected on the basis of at least 3 spermiograms, long standing infertility, normal LH, FSH, prolactin and testosterone serum levels and lack of evidence of any other pathologic involvement. Testicular biopsies performed on these patients showed hypospermatogenesis with foci of alteration at the spermatid stage in some of them. D-Trp-6-LH-RH was administered im for 90 days as a dose of 5 μg every 2 days, 10 μg daily or 10 μg daily every 2 days. These was no significant improvement in the concentration of spermatozoa or in the motility and vitality parameters. Moreover, in 5 patients who received 10 μg daily, basal levels of LH and FSH and the response to LH-RH, decreased significantly during treatment, D-Trp-6-LH-RH at the dose used in this study does not seem useful for the treatment of oligoasthenozoospermia normogonadotropic patients.

UR - http://www.scopus.com/inward/record.url?scp=0020081008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020081008&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 171

EP - 178

JO - International Journal of Andrology

JF - International Journal of Andrology

SN - 0105-6263

IS - 2

ER -